Cencora to Acquire OneOncology to Expand Community Oncology Solutions

Key Takeaways COR to buy most remaining OneOncology equity for $3.6B, gaining greater strategic control of the platform.COR raised long-term U.S. Healthcare Solutions guidance to 7-10% operating income and 10-14% EPS growth.COR will fund the deal mainly with new debt, pause buybacks and expect neutral FY EPS near the low end.Cencora, Inc. (COR) recently agreed to acquire a majority of the remaining equity interests in OneOncology — a physician-led national platform that supports independent oncology practic ...